Generated by AI
Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide. Its current portfolio includes widely used treatments for chronic metabolic conditions as well as therapies for cancer and immune-related diseases, supported by ongoing commercial operations and regulated manufacturing capacity in the United States, Europe, and Asia. The company also advances diagnostics and specialty medicines that address complex medical needs in hospital, outpatient, and community settings. Eli Lilly and Company plays a significant role in the pharmaceutical market through its broad product lineup, large-scale distribution network, and focus on prescription medicines that are used in everyday clinical practice.
WebsiteLilly Corporate Center
Indianapolis, IN, 46285
United States
The latest articles about LLY.
Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.
Rhythm Pharmaceuticals rose 3.6% as traders cited an alert that Eli Lilly submitted a rival bid near $150 per share plus a contingent value right.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about LLY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.